NasdaqGS:GH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Guardant Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: GH's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.8%

GH

0.1%

US Healthcare

2.1%

US Market


1 Year Return

43.2%

GH

12.1%

US Healthcare

19.8%

US Market

Return vs Industry: GH exceeded the US Healthcare industry which returned 12% over the past year.

Return vs Market: GH exceeded the US Market which returned 19.7% over the past year.


Shareholder returns

GHIndustryMarket
7 Day3.8%0.1%2.1%
30 Day0.9%5.8%8.1%
90 Day17.2%8.3%6.0%
1 Year43.2%43.2%13.6%12.1%22.5%19.8%
3 Yearn/a32.4%27.0%46.5%36.8%
5 Yearn/a77.6%65.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Guardant Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Guardant Health undervalued compared to its fair value and its price relative to the market?

10.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GH is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: GH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GH is overvalued based on its PB Ratio (10.3x) compared to the US Healthcare industry average (3.2x).


Next Steps

Future Growth

How is Guardant Health forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

45.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GH's revenue (25.2% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: GH's revenue (25.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GH is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Guardant Health performed over the past 5 years?

-21.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GH is currently unprofitable.

Growing Profit Margin: GH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GH is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.

Accelerating Growth: Unable to compare GH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (22.6%).


Return on Equity

High ROE: GH has a negative Return on Equity (-15.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is Guardant Health's financial position?


Financial Position Analysis

Short Term Liabilities: GH's short term assets ($1.1B) exceed its short term liabilities ($72.0M).

Long Term Liabilities: GH's short term assets ($1.1B) exceed its long term liabilities ($41.5M).


Debt to Equity History and Analysis

Debt Level: GH is debt free.

Reducing Debt: GH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GH has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.7% each year


Next Steps

Dividend

What is Guardant Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Helmy Eltoukhy (41 yo)

7.83yrs

Tenure

US$914,906

Compensation

Dr. Helmy Eltoukhy, PhD is the Co-founder of Guardant Health Inc. and serves as its Chief Executive Officer and Director. Dr. Eltoukhy is a serial entrepreneur and pioneer in the biotech industry. He joine...


CEO Compensation Analysis

Compensation vs Market: Helmy's total compensation ($USD914.91K) is below average for companies of similar size in the US market ($USD10.79M).

Compensation vs Earnings: Helmy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
AmirAli Talasaz
Presidentno dataUS$914.91k3.16%
$ 356.0m
Helmy Eltoukhy
Co-Founder7.83yrsUS$914.91k3.48%
$ 392.4m
Derek Bertocci
Chief Financial Officer4.33yrsUS$2.13m0.0064%
$ 717.3k
Richard Lanman
6.17yrsUS$3.07m0%
$ 0
Kumud Kalia
Chief Information Officer0.83yrno datano data
John Saia
Senior Vice President0.83yrno data0.012%
$ 1.4m
Amelia Merrill
Vice President of Peopleno datano datano data
Mark Jacobstein
Chief User Engagement Officerno datano datano data
Andy Ament
Senior Vice President of Operations0.67yrno datano data
Daniel Simon
Senior Vice President of Biopharma Business Developmentno datano datano data
Nitin Sood
Senior Vice President of Product Developmentno datano datano data

4.3yrs

Average Tenure

47yo

Average Age

Experienced Management: GH's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
AmirAli Talasaz
Presidentno dataUS$914.91k3.16%
$ 356.0m
Helmy Eltoukhy
Co-Founder7.83yrsUS$914.91k3.48%
$ 392.4m
Stanley Meresman
Independent Director2.5yrsUS$314.58k0.0041%
$ 457.2k
Ian Clark
Lead Independent Directorno dataUS$324.58k0.0046%
$ 522.5k
Samir Kaul
Independent Director6.58yrsUS$299.58k0.056%
$ 6.3m
Bahija Jallal
Independent Director1.58yrsUS$464.52k0.0056%
$ 630.6k
Vijaya Gadde
Director0.42yrno data0.0047%
$ 529.3k

2.0yrs

Average Tenure

46yo

Average Age

Experienced Board: GH's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.


Top Shareholders

Company Information

Guardant Health, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Guardant Health, Inc.
  • Ticker: GH
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$11.261b
  • Shares outstanding: 99.97m
  • Website: https://guardanthealth.com

Number of Employees


Location

  • Guardant Health, Inc.
  • 505 Penobscot Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2018
GH *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNOct 2018
5GHDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2018

Biography

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cance...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:29
End of Day Share Price2020/11/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.